(0.11%) 5 254.21 points
(0.00%) 39 762 points
(0.01%) 16 401 points
(1.52%) $82.59
(0.52%) $1.727
(2.02%) $2 234.80
(0.97%) $24.99
(1.48%) $923.15
(0.27%) $0.926
(0.53%) $10.83
(0.01%) $0.791
(0.24%) $92.66
Live Chart Being Loaded With Signals
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...
Stats | |
---|---|
Today's Volume | 2.39M |
Average Volume | 3.41M |
Market Cap | 157.33B |
EPS | ¥0 ( 2024-01-31 ) |
Next earnings date | ( ¥-210.31 ) 2024-05-12 |
Last Dividend | ¥7.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -0.910 |
ATR14 | ¥0.481 (0.12%) |
Volume Correlation
Sumitomo Pharma Co., Ltd. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sumitomo Pharma Co., Ltd. Correlation - Currency/Commodity
Sumitomo Pharma Co., Ltd. Financials
Annual | 2022 |
Revenue: | ¥555.54B |
Gross Profit: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
Q3 | 2023 |
Revenue: | ¥82.39B |
Gross Profit: | ¥49.52B (60.11 %) |
EPS: | ¥-125.77 |
Q2 | 2023 |
Revenue: | ¥76.96B |
Gross Profit: | ¥47.06B (61.16 %) |
EPS: | ¥-72.68 |
Q1 | 2023 |
Revenue: | ¥75.69B |
Gross Profit: | ¥45.26B (59.79 %) |
EPS: | ¥-97.81 |
Financial Reports:
No articles found.
Sumitomo Pharma Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥14.00 (N/A) |
¥0 (N/A) |
¥7.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.75 | 2000-03-28 |
Last Dividend | ¥7.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | ¥382.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9962.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8977.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
8125.T | Ex Dividend Knight | 2024-02-28 | Annually | 0 | 0.00% | |
7483.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6752.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6136.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
4887.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4091.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3315.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2395.T | Ex Dividend Junior | 2023-09-28 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.526 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.164 | 1.200 | -5.46 | -6.56 | [0 - 0.3] |
returnOnEquityTTM | -0.440 | 1.500 | -6.00 | -9.00 | [0.1 - 1] |
payoutRatioTTM | -0.0161 | -1.000 | -0.161 | 0.161 | [0 - 1] |
currentRatioTTM | 0.627 | 0.800 | -1.864 | -1.491 | [1 - 3] |
quickRatioTTM | 0.333 | 0.800 | -2.75 | -2.20 | [0.8 - 2.5] |
cashRatioTTM | 0.0866 | 1.500 | -0.630 | -0.945 | [0.2 - 2] |
debtRatioTTM | 0.389 | -1.500 | 3.52 | -5.29 | [0 - 0.6] |
interestCoverageTTM | -8.87 | 1.000 | -4.40 | -4.40 | [3 - 30] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 1.199 | -1.500 | 5.20 | -7.81 | [0 - 2.5] |
grossProfitMarginTTM | 0.599 | 1.000 | 3.34 | 3.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.536 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.669 | 1.000 | -4.83 | -4.83 | [0.2 - 2] |
assetTurnoverTTM | 0.312 | 0.800 | -1.256 | -1.005 | [0.5 - 2] |
Total Score | -5.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.910 | 1.000 | -0.193 | 0 | [1 - 100] |
returnOnEquityTTM | -0.440 | 2.50 | -3.86 | -9.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.759 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.0161 | 1.500 | -0.161 | 0.161 | [0 - 1] |
pegRatioTTM | -2.63 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.834 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.01 |
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators